APEN:NSD-Apollo Endosurgery Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 6.74

Change

+0.18 (+2.74)%

Market Cap

USD 0.27B

Volume

0.22M

Avg Analyst Target

USD 11.00 (+63.20%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


APEN Stock Forecast & Price:
Based on the Apollo Endosurgery Inc stock forecasts from 2 analysts, the average analyst target price for Apollo Endosurgery Inc is USD 11.00 over the next 12 months. Apollo Endosurgery Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Apollo Endosurgery Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Apollo Endosurgery Inc’s stock price was USD 6.74. Apollo Endosurgery Inc’s stock price has changed by +4.33% over the past week, +58.59% over the past month and -26.50% over the last year.

About Apollo Endosurgery Inc (APEN:NSD)

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to s ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-12 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

+1.59 (+1.80%)

USD34.96B 205.21 88.80
PODD Insulet Corporation

+6.62 (+2.51%)

USD18.33B 498.26 127.76
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD ABIOMED Inc

+2.66 (+0.91%)

USD13.28B 58.91 43.54
SWAV Shockwave Medical Inc

+7.61 (+2.70%)

USD10.03B 341.73 123.23
BRKR Bruker Corporation

-0.19 (-0.31%)

USD9.18B 34.44 19.15
IART Integra LifeSciences Holdings

+0.89 (+1.58%)

USD4.72B 28.97 16.36
IRTC iRhythm Technologies Inc

-0.38 (-0.25%)

USD4.56B N/A -39.96
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67
TNDM Tandem Diabetes Care Inc

+0.33 (+0.62%)

USD3.64B 707.88 556.41

ETFs Containing APEN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -20.05% 65% D 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.05% 65% D 43% F
Trailing 12 Months  
Capital Gain -24.27% 70% C- 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.27% 70% C- 43% F
Trailing 5 Years  
Capital Gain 49.45% 71% C- 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.45% 71% C- 64% D
Average Annual (5 Year Horizon)  
Capital Gain 51.60% 80% B- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.60% 80% B- 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 157.51% 17% F 7% F
Risk Adjusted Return 32.76% 64% D 66% D
Market Capitalization 0.27B 57% F 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.43 28% F 17% F
Price / Cash Flow Ratio -18.47 85% B 81% B-
EV/EBITDA -9.78 82% B- 84% B
Management Effectiveness  
Return on Equity -141.15% 17% F 10% F
Return on Invested Capital -21.72% 49% F 32% F
Return on Assets -15.39% 43% F 26% F
Debt to Equity Ratio 86.53% 31% F 25% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.79 77% C+ 68% D+
Short Percent 3.99% 45% F 40% F
Beta 2.47 9% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector